Post-cross-over activity of regorafenib (RE) in soft tissue sarcoma: Analysis from the REGOSARC trial.

Nuria Kotecki,Thomas Brodowicz,Axel Le Cesne,Marie-Cécile Le Deley,Jennifer Wallet,Antoine Italiano,Jean-Yves Blay,François Bertucci,Christine Chevreau,Sophie Piperno-Neumann,Emmanuelle Bompas,S Bastien Salas,Christophe Perrin,Corinne Delcambre,Bernadette Lieg-Atzwanger,Maud Toulmonde,Isabelle Ray-Coquard,Julien Théry,Olivier Mir,Nicolas Penel

Post-cross-over activity of regorafenib (RE) in soft tissue sarcoma: Analysis from the REGOSARC trial.

2017

11052Background: Based on the placebo (PBO) controlled phase 2 trial (Mir, Lancet Oncol 2016), RE has shown to be an active drug in patients (pts) with leiomyosarcoma (LMS), synovial sarcoma (SS) a...

Keywords:

Regorafenib
Soft tissue sarcoma
Pathology
Medicine
Leiomyosarcoma
Oncology
in patient
Internal medicine
Placebo
cross over
Synovial sarcoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations